Earnings Feed
Start Free
BIO-TECHNE Corp·4

Apr 16, 4:19 PM ET

Kelderman Kim 4

4 · BIO-TECHNE Corp · Filed Apr 16, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne CEO Kim Kelderman Exercises Options, Sells Shares

What Happened
Kim Kelderman, CEO of Bio-Techne (TECH), exercised options to acquire 36,500 shares on 2026-04-14. On the same date she surrendered 32,088 shares to satisfy tax withholding obligations, a disposition valued at $1,882,282 (32,088 shares × $58.66). Net of the withholding, Kelderman received 4,412 shares.

Key Details

  • Transaction date: 2026-04-14; Form 4 filed 2026-04-16 (timely).
  • Exercise reported as derivative conversion (code M) for 36,500 shares at $0.00 (reported exercise price).
  • Tax withholding reported (code F): 32,088 shares disposed at $58.66 per share for $1,882,282.
  • Net new shares retained from the exercise: 4,412 shares (36,500 acquired − 32,088 withheld).
  • Footnote indicates the options were fully exercisable (Footnote F1).
  • Filing does not disclose total shares held by Kelderman after the transaction in the details you provided.

Context
This appears to be a routine option exercise with shares withheld to pay taxes (a common practice), rather than an open-market sale intended as a liquidity or investment signal. Code reference: M = option exercise/conversion; F = payment of exercise price or tax liability.

Insider Transaction Report

Form 4
Period: 2026-04-14
BIO-TECHNE CorpTECH
Kelderman Kim
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-04-14+36,500→ 85,165 total
  • Tax Payment

    Common Stock

    2026-04-14$58.66/sh−32,088$1,882,282→ 53,077 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1]
    2026-04-14−36,500→ 73,036 total
    Exercise: $47.60Exp: 2026-08-07→ Common Stock (36,500 underlying)
Holdings

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $66.97Exp: 2027-08-05→ Common Stock (115,724 underlying)
    115,724

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $120.46Exp: 2028-08-06→ Common Stock (25,944 underlying)
    25,944

  • Stock Options (Right to Buy)

    [F1]
    Exercise: $94.52Exp: 2029-08-15→ Common Stock (28,940 underlying)
    28,940

  • Performance Restricted Stock Units

    [F2][F3]
    → Common Stock (8,873 underlying)
    8,873

  • Performance Stock Options (Right to Buy)

    [F3]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (23,881 underlying)
    23,881

  • Stock Options (Right to Buy)

    [F4]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (29,391 underlying)
    29,391

  • Stock Options (Right to Buy)

    [F5]
    Exercise: $52.83Exp: 2030-11-01→ Common Stock (38,252 underlying)
    38,252

  • Performance Restricted Stock Units

    [F2][F3]
    → Common Stock (9,423 underlying)
    9,423

  • Performance Stock Options (Right to Buy)

    [F3]
    Exercise: $68.54Exp: 2031-02-01→ Common Stock (25,945 underlying)
    25,945

  • Stock Options (Right to Buy)

    [F6]
    Exercise: $68.54Exp: 2031-02-01→ Common Stock (51,890 underlying)
    51,890

  • Performance Restricted Stock Units

    [F2][F7]
    → Common Stock (51,261 underlying)
    51,261

  • Restricted Stock Units

    [F2][F8]
    → Common Stock (17,087 underlying)
    17,087

  • Stock Options (Right to Buy)

    [F9]
    Exercise: $74.91Exp: 2034-08-15→ Common Stock (69,061 underlying)
    69,061

  • Performance Restricted Stock Units

    [F2][F10]
    → Common Stock (70,708 underlying)
    70,708

  • Restricted Stock Units

    [F2][F11]
    → Common Stock (35,354 underlying)
    35,354

  • Stock Options (Right to Buy)

    [F12]
    Exercise: $53.60Exp: 2035-08-15→ Common Stock (90,441 underlying)
    90,441
Footnotes (12)
  • [F1]Fully exercisable.
  • [F10]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F11]11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
  • [F12]Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F3]Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F4]Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
  • [F5]Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
  • [F6]Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
  • [F7]Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F8]8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
  • [F9]Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
Signature
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.|2026-04-16

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES